Patient Volume vs Case Value: Which Grows Revenue Faster

Seventy-two percent of practices told the 2025 Dental Economics/Levin Group Annual Practice Survey that their production went up last year. Average annual production per doctor, including hygiene, went from $1,004,178 to $1,001,807, which is to say it went nowhere. Everyone got busier and nobody got richer.

Here's our call, and plenty of owners will hate it: for the roughly three in four practices that already describe themselves as busy enough, new-patient marketing is the most expensive revenue in dentistry, and we'd move next quarter's acquisition budget into diagnosis, imaging and case presentation instead. Not because volume doesn't work. Because volume costs four times as much per dollar of profit it delivers, and you can't out-schedule a fee index that's losing to inflation.

The $55,200 Hole Fee Increases Didn't Fill

Start with the squeeze, because it sets the size of the problem. Since January 2021, the dental reimbursement rate index averaged across all payer types has risen 19%, while overall inflation ran 27% and both dental equipment and supply prices and dental staff hourly earnings rose 23% each, according to the ADA Health Policy Institute's Q2 2026 dental economy update. Your fees went up less than your costs. That gap is the whole argument.

Run it on a million-dollar practice. Say you did $1,000,000 in 2021 at 62% overhead, so $620,000 of cost and $380,000 of profit. Do the identical procedure mix today and the reimbursement index puts you at $1,190,000. Apply the 23% cost increase to that overhead base and you're at $762,600. Profit lands at $427,400. Looks like a raise. It isn't: holding 2021 purchasing power at 27% inflation requires $482,600. You're short $55,200 a year on the same work. That's 31% of the $176,110 median annual wage for dentists in 2025 reported by the Bureau of Labor Statistics.

So the real question isn't "how do I grow." It's "what's the cheapest way to manufacture $55,200 of profit I used to have." And that answer depends entirely on which lever you pull.

Two Routes to $100,000, One of Them Costs $73,280

Take a practice at $1,000,000 of production with 1,600 active patients. Average annual production per patient is $625. You want $100,000 more production. There are two honest ways to get it.

Route one: more patients. At $625 a head you need 160 net new patients to land $100,000. At a fully loaded acquisition cost of $350 per new patient (ads, agency fee, the free exam you're writing off), that's $56,000 of spend. Those bodies need chairs: add one hygiene day a week at 8 hours and a $45 loaded hourly cost and you've committed $17,280. Supplies and lab on the new production at 11% add $11,000. Total incremental cost $84,280. Net profit from the whole campaign: $15,720. You spent $73,280 of discretionary money (marketing plus the staffing commitment) to clear that, which is 21 cents of profit per dollar deployed.

Route two: more per patient. Same $100,000, pulled from the 1,600 patients you already have. That's $62.50 more per patient per year. One additional crown, one scanned and accepted occlusal guard, one sequenced quadrant of perio therapy per fifteen or twenty patients gets you there. Cost side: $9,000 for treatment-plan coaching and a scripted case-presentation rebuild, plus $14,400 a year for a scanner or imaging lease at $1,200 a month, so $23,400. Higher-value cases carry more lab, so run supplies and lab at 18%, or $18,000. Total $41,400. Net profit: $58,600. That's $2.50 of profit per discretionary dollar.

Same top line. The case-value route nets 3.7 times what the volume route nets. Now go back to the $55,200 hole. Closing it through case value at a 58.6% incremental margin takes about $94,198 of added production. Closing it through new patients at a 15.7% incremental margin takes $351,145. That's $256,947 of extra production, roughly a second associate's worth, to end up in the same place.

Counting New Patients Instead of Pricing Chair Time

The mistake is almost universal among owners who came up in the 2010s growth playbook, and it's this: they track new patients per month as the headline number and never compute the margin on the marginal patient. The new-patient count is the easiest number in the practice to move and the least connected to what you take home. It's measured weekly on a whiteboard. Incremental margin is measured never.

Two groups make this error worst. The first is owners who hired a marketing agency before they fixed their hygiene reappointment rate, so they're paying $350 a head to replace patients walking out the back door. The second is owners whose schedule is already 90% full, where every new patient doesn't add production, it displaces production. When a crown prep gets pushed three weeks because the chair is full of new-patient exams, volume growth is actively cannibalizing case value.

Our view: new patients per month is the wrong headline metric for a practice at capacity. The right one is production per patient visit, tracked monthly, split by provider. If that number is flat while your patient count rises, you're buying revenue at 21 cents on the dollar and calling it growth.

The 26% Who Should Ignore Everything Above

The volume argument isn't wrong, it's conditional. In Q2 2026, 26% of U.S. dentists reported they were "not busy enough" and could have treated more patients, down from 32% in Q1 2026 and 33% in Q4 2025, per the ADA Health Policy Institute. If you're in that quarter of the market, your math inverts. You already paid for the chairs, the assistants and the rent. Incremental patients land on fixed cost you're eating anyway, so the marginal margin on a new patient isn't 15.7%, it's closer to 70%. Chase volume hard, and don't apologize for it.

The test is a number, not a feeling. Pull your last 90 days of scheduled doctor hours against available doctor hours. Under 80% use, buy patients. Over 90%, buying patients is buying a longer wait list and a more stressed team. Between the two, fix the mix before you fix the funnel.

And notice the trend line: that not-busy-enough share has fallen from 33% to 26% in two quarters. The pool of practices for whom volume is the cheap lever is shrinking fast. Meanwhile the Bureau of Labor Statistics projects dentist employment growing 6% from 2025 to 2035 off a base of 161,400 jobs, which is not the kind of supply growth that loosens anybody's schedule.

Five Operatories, $200,000 Each, and a $609,165 Spread

Here's the clearest evidence we have that chair count isn't the constraint. In the Practice Market Index, our dataset of 925 dental practices currently listed for sale, the median practice reports $957,588 in collections (n=753) out of a median of 5 operatories (n=754). Collections per operatory run a median of $200,000, with the middle half of listings between $146,875 and $268,708 (n=643).

These are practices on the asking side of the market, not a snapshot of all practices. But the spread is the story. A chair at the 75th percentile produces $121,833 more than a chair at the 25th. Across five operatories, that's $609,165 of difference between two practices with identical square footage, identical equipment count and, often, a similar patient head count. Nobody built their way to that gap. They diagnosed their way there.

Which is why we wouldn't fund an operatory build-out as a growth plan for a practice doing under $180,000 per existing chair. You don't have a capacity problem. You have a $53,125 per-chair diagnosis problem, and adding a sixth room makes it a six-room version of the same problem.

Where This Argument Breaks

Case value has a ceiling too, and it's ethical before it's economic. There is a version of "raise per-patient production" that is simply overtreatment, and it ends in chart audits, refund demands and a reputation you can't buy back at $350 a head. The legitimate version is narrower: diagnosing what's actually there, presenting it in full instead of in fragments, sequencing it so patients can say yes, and not discounting it to death through plan participation you never re-priced. If your unaccepted treatment report is thin and your fee schedule is current, then yes, volume is your only remaining lever, and you should go get it.

The other break point is fee value itself. With the reimbursement index up only 19% against 23% staff cost growth, a practice heavily weighted to low-reimbursement plans can raise case value in procedure terms and still lose in dollar terms. For those practices the first move isn't volume or value. It's the plan mix.

Pull Two Numbers Before Friday

Run your scheduled-to-available doctor hours for the last 90 days, and run production per patient visit by provider for the same window. If use is under 80%, approve the marketing spend and stop reading. If it's over 90% and production per visit is flat year over year, cancel one acquisition channel this month and put that exact dollar amount into case-presentation training and your unaccepted treatment follow-up list. Then recheck production per visit in 60 days, because that's the number that tells you whether anything actually changed.

We'll be watching two things. If the ADA's Q3 update shows the not-busy-enough share dropping below 20%, capacity becomes the binding constraint for nearly everyone and the volume route gets worse still. If the reimbursement index starts closing on inflation, we'd soften this call. Until one of those moves, benchmark where your money is actually going first: our overhead calculator will show you the incremental margin you're working with before you commit another dollar to either route, so run your own numbers and see which lever your practice can afford.